NGNE — Neurogene Income Statement
0.000.00%
Last trade - 00:00- $281.82m
- -$10.72m
- $0.93m
- 58
- 16
- 11
- 18
Annual income statement for Neurogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.925 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.7 | 60.7 | 59.1 | 39.2 | 83.5 |
| Operating Profit | -33.7 | -60.7 | -59.1 | -39.2 | -82.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -33.3 | -60.7 | -57.6 | -36.3 | -75.1 |
| Net Income After Taxes | -33.3 | -60.7 | -57.6 | -36.3 | -75.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -33.3 | -60.7 | -57.6 | -36.3 | -75.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -33.3 | -60.7 | -57.6 | -36.3 | -75.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -79.3 | -110 | -104 | -4.11 | -4.27 |